Volume 9 Supplement 1

Basic science, rationale, background and future of denosumab: a RANK ligand inhibitor

Reviews

Edited by Edward M Schwarz and Christopher T Ritchlin

Supported by an unrestricted grant from Amgen Inc.

  1. Review

    Biology of RANK, RANKL, and osteoprotegerin

    The discovery of the receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin (OPG) system and its role in the regulation of bone resorption exemplifies how both serendipity and a logic-base...

    Brendan F Boyce and Lianping Xing

    Arthritis Research & Therapy 2007 9(Suppl 1):S1

    Published on: 29 June 2007

  2. Review

    Erosive arthritis

    Inflammation and degradation of bone are two closely linked processes. Chronic inflammatory arthritis not only leads to inflammatory bone loss but it also involves local erosion of articular bone. This osteo-d...

    Georg Schett

    Arthritis Research & Therapy 2007 9(Suppl 1):S2

    Published on: 29 June 2007

  3. Review

    Role of RANKL inhibition in osteoporosis

    When the rate of bone resorption exceeds that of bone formation, destruction of bone tissue occurs, resulting in a fragile skeleton. The clinical consequences, namely osteoporosis and fragility fractures, are ...

    Michael McClung

    Arthritis Research & Therapy 2007 9(Suppl 1):S3

    Published on: 29 June 2007

  4. Review

    Multiple myeloma/hypercalcemia

    Multiple myeloma, a cancer of plasma cells, is associated with excessive tumor-induced, osteoclast-mediated bone destruction. Hypercalcemia remains the most frequent metabolic complication of myeloma in patien...

    Babatunde O Oyajobi

    Arthritis Research & Therapy 2007 9(Suppl 1):S4

    Published on: 29 June 2007

  5. Review

    Tumor metastasis to bone

    Establishment of skeletal metastasis involves bidirectional interactions between the tumor cell and the cellular elements in the bone microenvironment. A better understanding of the pathophysiology of bone met...

    Mandeep S Virk and Jay R Lieberman

    Arthritis Research & Therapy 2007 9(Suppl 1):S5

    Published on: 29 June 2007

  6. Review

    Clinical development of anti-RANKL therapy

    The receptor activator of nuclear factor-κB ligand (RANKL), its cognate receptor RANK, and its natural decoy receptor osteoprotegerin have been identified as the final effector molecules of osteoclastic bone r...

    Edward M Schwarz and Christopher T Ritchlin

    Arthritis Research & Therapy 2007 9(Suppl 1):S7

    Published on: 29 June 2007

Logo

Advertisement